fda warning letter compounding semaglutide october 2025 February 17, 2026: Pennsylvania pharmacy earns another – Partnership for Safe Medicines Beyond the Headlines: FDA Warning

It is a detour

Some researchers worry that the additional receptor complexity will prove harder to tolerate than dual agonists

Monitoring high-level athletes for drug misuse is nothing new, but the World Anti-Doping Agency (WADA) surprised many people recently by deciding to track the use of GLP-1 drugs, such as the diabetes and obesity treatments Ozempic (semaglutide) and Zepbound (tirzepatide)

With generics arriving next year as patents expire, the impact on Canadian shoppers will be even bigger

Complications from the Trulicity pill are the subject of lawsuits, because patients say they were not told that Trulicity could raise their risk of vision loss, stomach paralysis, and other health issues